Leading Clinical Trial Supplies Clinical Phase Markets Databank
The Clinical Trial Supplies market was valued at $2,090.0 Million in 2020, and is projected to reach $3,991.9 Million by 2029 growing at a CAGR of 7.50% from 2021 to 2029. Phase III segment is expected to be the highest contributor to this market, with $771.8 Million in 2020, and is anticipated to reach $1,486.6 Million by 2029, registering a CAGR of 7.60%. Phase III and Phase II segments collectively expected to account for about 66.9% share of the Clinical Trial Supplies market in 2020, with the former constituting around 36.9% share. Phase III and Phase II segments are expected to witness significant growth rates at a CAGR of 7.60% and 7.58% respectively, during the forecast period. Presently, share of these two segments is estimated to be around 66.9% in the overall Clinical Trial Supplies market in 2020, and is anticipated to reach 67.4% by 2029.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook